I have been working with the Barnes group alongside my clinical training for several years. Much of my work has been focused on translational cellular immunology in immune mediated hepatobiliary disease. Recently I have been awarded a Welcome Trust Clinical Fellowship to undertake a PhD on HBV immunotherapy within the vaccine group.
I am interested in harnessing cellular immunology to understand disease pathogenesis and develop novel treatment strategies for hepatobiliary conditions.
IgG4-Related Disease Study: Natural history and pathogenesis
Immunotherapy for chronic Hepatitis B infection
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.
Cargill T. et al, (2023), JHEP reports : innovation in hepatology, 5
NK cells limit therapeutic vaccine-induced CD8+T cell immunity in a PD-L1-dependent manner.
Diniz MO. et al, (2022), Science translational medicine, 14
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Marjot T. et al, (2021), Journal of hepatology, 74, 567 - 577
The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.
Cargill T. and Culver EL., (2021), Frontiers in immunology, 12
What is the probability that this patient, who presents to a UK hospital, will be diagnosed with Covid-19? Prospective validation of the open-source CovidCalculatorUK resource
Chapman G. et al, (2020)